← FDA DRUG APPROVALS

FDA ANDA · ANDA062200

ERYTHROMYCIN ETHYLSUCCINATE

Sponsor: ALPHARMA US PHARMS

APPLICATION
ANDA062200
TYPE
ANDA
ORIGINAL APPROVAL
1981-08-11
LATEST ACTION
2002-12-23
ROUTE
ORAL
DOSAGE FORM
SUSPENSION
MARKETING STATUS
Discontinued

Products

ERYTHROMYCIN ETHYLSUCCINATEDiscontinued
ERYTHROMYCIN ETHYLSUCCINATE EQ 400MG BASE/5ML · SUSPENSION · ORAL
ERYTHROMYCIN ETHYLSUCCINATEDiscontinued
ERYTHROMYCIN ETHYLSUCCINATE EQ 200MG BASE/5ML · SUSPENSION · ORAL

Approval history

2002-12-23Labeling · Supplement 42AP
2000-09-25Manufacturing (CMC) · Supplement 41AP
1999-05-26Manufacturing (CMC) · Supplement 40AP
1999-05-26Manufacturing (CMC) · Supplement 39AP
1998-11-17Labeling · Supplement 38AP
1996-04-25Manufacturing (CMC) · Supplement 36AP
1995-05-08Manufacturing (CMC) · Supplement 35AP
1993-06-07Labeling · Supplement 34AP
1992-05-29Manufacturing (CMC) · Supplement 31AP
1992-04-06Manufacturing (CMC) · Supplement 32AP
1992-01-31Labeling · Supplement 33AP
1991-06-26Manufacturing (CMC) · Supplement 26AP
1991-06-26Manufacturing (CMC) · Supplement 27AP
1991-05-22Manufacturing (CMC) · Supplement 24AP
1990-09-28Manufacturing (CMC) · Supplement 30AP
1989-11-06Manufacturing (CMC) · Supplement 20AP
1989-11-06Manufacturing (CMC) · Supplement 25AP
1989-07-07Manufacturing (CMC) · Supplement 21AP
1989-01-26Manufacturing (CMC) · Supplement 18AP
1981-08-11OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →